divarasib

AXP000025.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Genentech
Sponsor
Genentech (Roche)

Names

NameTypeSource
divarasibpreferred name, INNcurator, ncit
GDC-6036codencit
RG6330codencit

Cross-references

NCI Thesaurus
C173995
Wikidata
Q123118541
FDA UNII
E6S21PVT91

Approvals

No regulatory approval recorded.

Clinical trials (15)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07541170A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 32026-10-062032-01-31400Non-small Cell Lung Cancer
NCT06793215A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 32025-10-242028-11-30600KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer
NCT06835465A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 12025-02-212025-05-0618Healthy Participants
NCT06734208A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic FunctionCompletedPhase 12025-01-312025-11-2731Hepatic Impairment
NCT06690138A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 12024-11-152025-02-1118Healthy Participants
NCT06677957A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy ParticipantsCompletedPhase 12024-11-062024-12-3019Healthy Participants
NCT06497556A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive not recruitingPhase 32024-09-232026-05-19338KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer
NCT05789082A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/22023-06-202032-01-29320Non-Small Cell Lung Cancer
NCT05862285A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 32023-06-012033-03-01200Cancer
NCT04929223A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 12021-10-222030-08-31542Metastatic Colorectal Cancer
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive not recruitingPhase 22021-01-182032-09-25920Solid Tumors
NCT04302025A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active not recruitingPhase 22020-11-062026-11-3099Non-small Cell Lung Cancer
NCT04449874A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive not recruitingPhase 12020-07-292027-12-31498Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer
NCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active not recruitingPhase 2/32017-09-222027-06-301000Non-Small Cell Lung Cancer
NCT07783009An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung CancerAvailableNon-Small Cell Lung Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42929675Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.The New England journal of medicine2026cited by trial NCT06497556
PMID 40086048Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.European journal of cancer (Oxford, England : 1990)2025cited by trial NCT04589845
PMID 40525978Update on Liquid Biopsy.Radiology2025cited by trial NCT03178552
PMID 40632992Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025cited by trial NCT04449874
PMID 41213248Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT04589845
PMID 38052910Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Nature medicine2024cited by trial NCT04449874
PMID 38190582Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.JCO precision oncology2024cited by trial NCT03178552
PMID 38898120Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.Nature medicine2024cited by trial NCT03178552
PMID 38995268Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research2024name in title: divarasib
PMID 37611121Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.The New England journal of medicine2023cited by trial NCT04449874
PMID 35995953Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.Nature medicine2022cited by trial NCT03178552

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41506251In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality.Journal of the American Society for Mass Spectrometry2026name in abstract: GDC-6036
PMID 41766690Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C.Journal of medicinal chemistry2026name in title: divarasib
PMID 41769711Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C.Journal of medicinal chemistry2026name in abstract: divarasib
PMID 41784211A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Cancer investigation2026name in abstract: divarasib
PMID 42098425Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.Journal of neuro-oncology2026name in abstract: divarasib
PMID 42365001Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model.Nature communications2026name in abstract: divarasib
PMID 42485897Development and validation of an LC-MS/MS method for the quantification of the KRASG12C inhibitor divarasib.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences2026name in title: divarasib
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: divarasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: divarasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: divarasib
PMID 42633623A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib.Chimia2026name in title: divarasib
PMID 42759542Targeting KRAS-Mutant Lung Cancers.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: divarasib
PMID 42841489Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.Molecular cancer therapeutics2026name in abstract: divarasib
PMID 42945155Divarasib Bests 1st-Generation KRASG12C Inhibitors.Cancer discovery2026name in title: divarasib
PMID 42975930Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.Proceedings of the National Academy of Sciences of the United States of America2026name in abstract: divarasib
PMID 42984346Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.Molecular cancer therapeutics2026name in abstract: divarasib
PMID 43003982Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC.Nature reviews. Clinical oncology2026name in title: divarasib
PMID 39914665Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology2025name in abstract: divarasib
PMID 40023579In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans.Drug metabolism and disposition: the biological fate of chemicals2025name in abstract: divarasib
PMID 40116975Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.Medical oncology (Northwood, London, England)2025name in abstract: divarasib
PMID 40274247KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials.Critical reviews in oncology/hematology2025name in abstract: divarasib
PMID 40297021Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review.Clinical Medicine Insights. Oncology2025name in abstract: divarasib
PMID 40447141Recent advances in therapeutic targeting of the KRAS pathway in cancer.Pharmacology & therapeutics2025name in abstract: divarasib
PMID 40597785The complex journey of targeting RAS in oncology.BMC cancer2025name in abstract: GDC-6036
PMID 40608319RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.Cancer research2025name in abstract: divarasib
PMID 40640254Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations.Scientific reports2025name in title: GDC-6036
PMID 41408054Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy.Nature communications2025name in abstract: divarasib
PMID 38542278Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.International journal of molecular sciences2024name in abstract: divarasib
PMID 38739329Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.Targeted oncology2024name in title: divarasib
PMID 39051157High Resolution Ion Mobility Enables the Structural Characterization of Atropisomers of GDC-6036, a KRAS G12C Covalent Inhibitor.Journal of the American Society for Mass Spectrometry2024name in title: GDC-6036
PMID 39360933An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Future oncology (London, England)2024name in abstract: divarasib
PMID 40391409The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement.Small GTPases2024name in title: divarasib
PMID 36876898Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry.Analytical chemistry2023name in abstract: GDC-6036
PMID 37162129Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036.Organic letters2023name in title: GDC-6036
PMID 37673947Early promising results with the novel KRASG12C inhibitor divarasib.Nature reviews. Clinical oncology2023name in title: divarasib
PMID 37774359Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.Journal of medicinal chemistry2023name in abstract: divarasib
PMID 36083155Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.Analytical chemistry2022name in abstract: GDC-6036
PMID 36326518Atroposelective Negishi Coupling Optimization Guided by Multivariate Linear Regression Analysis: Asymmetric Synthesis of KRAS G12C Covalent Inhibitor GDC-6036.Journal of the American Chemical Society2022name in title: GDC-6036
PMID 36358848KRAS in NSCLC: State of the Art and Future Perspectives.Cancers2022name in abstract: GDC-6036

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R21CA297690Noncovalent interaction of mutant KRAS inhibitorsDUKE UNIVERSITYCHI, JEN-TSAN ASHLEY2025–2025name in abstract: divarasib

Notes

KRAS G12C covalent. Roche code RG6330. UNII is free base; adipate salt is separate NCIt C203123 / UNII OA9191WV3C.

How to cite

divarasib (AXP000025.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000025.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.